| 英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
|---|---|---|---|---|---|---|
|
BRD76
|
32703-82-5 |
6-叔丁基-2,3-二氰基萘
|
6-叔丁基-2,3-二氰基萘;6-叔丁基-2,3-萘二甲腈;6-(叔丁基)萘-2,3-二腈;6-叔丁基萘-2,3-二甲腈;2,3-NAPHTHALENEDICARBONITRILE,6-(1,1-DIMETHYLETHYL)-
|
C16H14 N2 |
234.3 | |
|
Naspm tri hydrochloride
|
1049731-36-3 |
N-[3-[[4-[(3-氨基丙基)氨基]丁基]氨基]丙基]-1-萘乙酰胺三盐酸盐
|
N-[3-[[4-[(3-氨基丙基)氨基]丁基]氨基]丙基]-1-萘乙酰胺三盐酸盐
|
C22H37Cl3N4O |
479.91 | |
|
6a,7,8,9-Tetrahydro-2H-[1,4]dioxino[2',3':4,5]benzo[1,2-e]pyrrolo[2,1-b][1,3]oxazin-11(3H)-one
|
191744-13-5 |
2,3,6A,7,8,9-六氢-11H-1,4-二恶烷并[2,3-G]吡咯并[2,1-B][1,3]苯并恶嗪-11-酮
|
2,3,6A,7,8,9-六氢-11H-1,4-二恶烷并[2,3-G]吡咯并[2,1-B][1,3]苯并恶嗪-11-酮
|
C13H13NO4 |
247.249 | |
|
Shz-1
|
326886-05-9 |
苯磺酸[(5-溴-2-羟基苯基)亚甲基]酰肼
|
苯磺酸[(5-溴-2-羟基苯基)亚甲基]酰肼
|
C13H11BrN2O3S |
355.20704 | |
|
BIX
|
101714-41-4 |
硫氰酸 2-(3,4-二羟基苯基)-2-氧代乙酯
|
硫氰酸 2-(3,4-二羟基苯基)-2-氧代乙酯
|
C9H7NO3S |
209.22178 | |
|
PF-06463922
|
1454846-35-5 |
劳拉替尼(PF643922)
|
CS-1727;劳拉替尼;LORLATINIB API;劳拉替尼3922;INC280INC280;劳拉替尼(PF0643922);劳拉替尼 劳拉替尼;PF06463922;PF-06463922;PF 06463922
|
C21H19FN6O2 |
406.412963 | 813-704-5 |
|
A-867744
|
1000279-69-5 |
4-[5-(4-氯苯基)-2-甲基-3-丙酰基吡咯-1-基]苯磺酰胺
|
4-[5-(4-氯苯基)-2-甲基-3-丙酰基吡咯-1-基]苯磺酰胺;A-867744;A 867744;A867744;A 867744;A867744
|
C20H19ClN2O3S |
402.89446 | |
|
4-Methyl-2-(1-piperidinyl)-quinoline
|
5465-86-1 |
4-METHYL-2-(1-PIPERIDINYL)-QUINOLINE
|
4-甲基-2-(1-哌啶基)喹啉;ML-204;ML204
|
C15H18N2 |
226.31682 | |
|
Selexipag
|
475086-01-2 |
SELEXIPAG
|
赛乐西帕;2-{4-[(5,6-二苯基吡嗪-2-基)(异丙基);2-[4-[N-(5,6-二苯基哌嗪-2-基)-N-异丙基氨基]丁氧基}-N-(甲磺酰基)乙酰胺;塞乐西帕;西利帕格;赛乐西帕 1G;塞列西帕格杂质;赛乐西帕 SELEXIPAG INTERMEDIATES
|
C26H32N4O4S |
496.62168 | |
|
Propranolol EP Impurity A
|
36112-95-5 |
3-(萘酚基)-1,2-二羟基丙烷
|
普萘洛尔杂质A;3-(1-萘基氧基)-1,2-丙二醇;PROPRANOLOL-1;3-(萘酚基)-1,2-二羟基丙烷;普萘洛尔EP杂质A(普萘洛尔二醇衍生物);普萘洛尔EP杂质A
|
C13H14O3 |
||
|
Olcegepant
|
204697-65-4 |
N-[2-[5-氨基-1(S)-[4-(4-吡啶基)哌嗪-1-甲酰基]戊基氨基]-1(R)-(3,5-二溴-4-羟基苄基)-2-氧代乙基]-4-(2-氧代-1,2,3,4-四氢喹唑啉-3-基)哌啶-1-甲酰胺
|
N-[2-[5-氨基-1(S)-[4-(4-吡啶基)哌嗪-1-甲酰基]戊基氨基]-1(R)-(3,5-二溴-4-羟基苄基)-2-氧代乙基]-4-(2-氧代-1,2,3,4-四氢喹唑啉-3-基)哌啶-1-甲酰胺
|
C38H47Br2N9O5 |
869.64508 | |
|
NVP-ADW742
|
475488-23-4 |
5-(3-苄氧基苯基)-7-[反式-3-[(吡咯烷-1-基)甲基]环丁基]-7H-吡咯并[2,3-D]嘧啶-4-胺
|
5-(3-苄氧基苯基)-7-[反式-3-[(吡咯烷-1-基)甲基]环丁基]-7H-吡咯并[2,3-D]嘧啶-4-胺
|
C28H31N5O |
453.59 | |
|
UNC0642
|
1481677-78-4 |
2-(4,4-二氟-1-哌啶基)-6-甲氧基-N-[1-异丙基-4-哌啶基]-7-[3-(1-吡咯烷基)丙氧基]-4-喹唑啉胺
|
CS-1714;UNC-0642;UNC0642;UNC 0642;2-(4,4-二氟-1-哌啶基)-6-甲氧基-N-[1-异丙基-4-哌啶基]-7-[3-(1-吡咯烷基)丙氧基]-4-喹唑啉胺
|
C29H44F2N6O2 |
546.695466 | |
|
MPEP HYDROChloride
|
219911-35-0 |
2-甲基-6-(苯基乙炔基)吡啶盐酸盐
|
2-甲基-6-苯基乙炔基吡啶盐酸盐;2-甲基-6-(苯基乙炔基)吡啶盐酸盐;MPEP盐酸盐>98%
|
C14H11N.ClH |
229.709 | |
|
Monomethyl Auristatin E | MMAE
|
474645-27-7 |
一甲基澳瑞他汀 E
|
MMAE,(Vedotin)一甲基澳瑞他汀E;Microtubule抑制剂;CS-835;单甲基澳瑞他汀E;一甲基奥瑞他汀E;一甲基澳瑞他汀E;MICROTUBULE 抑制剂;MMAE;VEDOTIN;MONOMETHYL AURISTATIN E;MMAE,(VEDOTIN )一甲基澳瑞他汀 E
|
C39H67N5O7 |
717.97858 | |
|
A 438079 hydrochloride
|
899431-18-6 |
3-[[5-(2,3-二氯苯基)-1H-四唑-1-基]甲基]吡啶单盐酸盐
|
A-438079;A438079;A 438079;3-[[5-(2,3-二氯苯基)-1H-四唑-1-基]甲基]吡啶单盐酸盐
|
C13H10Cl3N5 |
342.611 | |
|
ONO-AE3-208
|
402473-54-5 |
4-氰基-2-[[2-(4-氟-1-萘基)-1-氧代丙基]氨基]苯基丁酸
|
ONO-AE3-208;AE 3-208;ONO AE3 208;AE 3-208;ONO AE3 208;4-氰基-2-[[2-(4-氟-1-萘基)-1-氧代丙基]氨基]苯基丁酸
|
C24H21FN2O3 |
404.439 | |
|
Cardiogenol C hydrochloride
|
1049741-55-0 |
2-[[2-[(4-甲氧基苯基)氨基]-4-嘧啶基]氨基]乙醇盐酸盐
|
2-[[2-[(4-甲氧基苯基)氨基]-4-嘧啶基]氨基]乙醇盐酸盐
|
C13H17ClN4O2 |
296.75 | |
|
GSK J1
|
1373422-53-7 |
N-[2-(2-吡啶基)-6-(1,2,4,5-四氢-3H-3-苯并氮杂卓-3-基)-4-嘧啶基]-BETA-丙氨酸
|
N-[2-(2-吡啶基)-6-(1,2,4,5-四氢-3H-3-苯并氮杂卓-3-基)-4-嘧啶基]-BETA-丙氨酸;GSK J1(锂盐);CS-2305
|
C22H23N5O2 |
389.45032 | 200-258-5 |
|
6-Chloro-n4-[3,5-difluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,4-pyrimidinediamine
|
867017-68-3 |
6-氯-N4-[3,5-二氟-4-[(3-甲基-1H-吡咯并[2,3-B]吡啶-4-基)氧]苯基]-2,4-嘧啶二胺
|
RHO-KINASE INHIBITOR;RHO KINASE INHIBITOR;6-氯-N4-[3,5-二氟-4-[(3-甲基-1H-吡咯并[2,3-B]吡啶-4-基)氧]苯基]-2,4-嘧啶二胺;RHO-KINASE INHIBITOR;RHO KINASE INHIBITOR;ROCK
|
C18H13ClF2N6O |
402.785226 |
药智官方微信
药智官方微博
